GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Kyorin Pharmaceutical Co Ltd (TSE:4569) » Definitions » 12-1 Month Momentum %

Kyorin Pharmaceutical Co (TSE:4569) 12-1 Month Momentum % : 2.07% (As of May. 22, 2024)


View and export this data going back to 2001. Start your Free Trial

What is Kyorin Pharmaceutical Co 12-1 Month Momentum %?

12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2024-05-22), Kyorin Pharmaceutical Co's 12-1 Month Momentum % is 2.07%.

The industry rank for Kyorin Pharmaceutical Co's 12-1 Month Momentum % or its related term are showing as below:

TSE:4569's 12-1 Month Momentum % is ranked better than
60.32% of 1109 companies
in the Drug Manufacturers industry
Industry Median: -9.57 vs TSE:4569: 2.07

Competitive Comparison of Kyorin Pharmaceutical Co's 12-1 Month Momentum %

For the Drug Manufacturers - Specialty & Generic subindustry, Kyorin Pharmaceutical Co's 12-1 Month Momentum %, along with its competitors' market caps and 12-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kyorin Pharmaceutical Co's 12-1 Month Momentum % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Kyorin Pharmaceutical Co's 12-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where Kyorin Pharmaceutical Co's 12-1 Month Momentum % falls into.



Kyorin Pharmaceutical Co  (TSE:4569) 12-1 Month Momentum % Calculation

12-1 Month Momentum % is calculated as following:

12-1 Month Momentum %=( Price 1-month ago / Price 12-month ago - 1 ) * 100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Kyorin Pharmaceutical Co  (TSE:4569) 12-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.


Kyorin Pharmaceutical Co 12-1 Month Momentum % Related Terms

Thank you for viewing the detailed overview of Kyorin Pharmaceutical Co's 12-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.


Kyorin Pharmaceutical Co (TSE:4569) Business Description

Traded in Other Exchanges
N/A
Address
6, Kanda Surugadai 4-chome, Chiyoda-ku, Tokyo, JPN, 101-8311
Kyorin Pharmaceutical Co Ltd is engaged in manufacturing and sale of pharmaceutical products. The company manages its business in two reportable segments namely Pharmaceutical Business and the Consumer Healthcare (Skincare) Business. The Pharmaceutical business focuses on producing and selling ethical drugs, generic drugs and over-the-counter drugs. The Consumer Healthcare (Skincare) Business mainly sells and purchases skincare products. The company's products include Kipres, for treating bronchial asthma and allergic rhinitis; Mucodyne, a mucoregulant; Pentasa, for treating ulcerative colitis and Crohn's disease; and Uritos, for treating overactive bladder. Majority of the company's revenue comes from domestic sales.

Kyorin Pharmaceutical Co (TSE:4569) Headlines

No Headlines